Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Looks To India As Next Partner To Host Foreign Regulatory Offices

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA is exploring whether to establish permanent regulatory offices in India, following the agency's announcement that it plans to do so in China, HHS Secretary Michael Leavitt said during a March 18 briefing in Washington, D.C., shortly after completing a trip to India

You may also be interested in...



U.S. FDA Plans Permanent Offices In China In Wake Of Heparin Scare

In the wake of a safety scare over Chinese-imported heparin API, U.S. FDA announced March 14 that it will establish permanent offices in Beijing, Guangzhou and Shanghai, staffed by eight full-time employees and five local Chinese nationals

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel